2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
Dominique Farge,Corinne Frere,Jean M Connors,Alok A Khorana,Ajay Kakkar,Cihan Ay,Andres Muñoz,Benjamin Brenner,Pedro H Prata,Dialina Brilhante,Darko Antic,Patricia Casais,María Cecilia Guillermo Esposito,Takayuki Ikezoe,Syed A Abutalib,Luis A Meillon-García,Henri Bounameaux,Ingrid Pabinger,James Douketis,Walter Ageno,Fernando Ajauro,Thierry Alcindor,Pantep Angchaisuksiri,Juan I. Arcelus,Raquel Barba,Ali Bazarbachii,Audrey Bellesoeur,Okba Bensaoula,Ilham Benzidia,Darius Bita,Viktoria Bitsadze,Dorit Blickstein,Mark Blostein,Isabel Bogalho,Antonio Brandao,Rodrigo Calado,Antoine Carpentier,Jose Manuel Ceresetto,Rufaro Chitsike,Jérôme Connault,Catarina Jacinto Correia,Benjamin Crichi,Erich V. De Paula,Ahmet M. Demir,Laure Deville,Ludovic Doucet,Vera Dounaevskaia,Cécile Durant,Martin Ellis,Joseph Emmerich,Anna Falanga,Carme Font,Enrique Gallardo,Thomas Gary,Filipe Gonçalves,Jean-Christophe Gris,Hiromi Hayashi,Adrian Hij,Luis Jara-Palomares,David Jiménez,Jamilya Khizroeva,Michel N'Guessan,Florian Langer,Claire Le Hello,Christine Le Maignan,Ramón Lecumberri,Lai Heng Lee,Zachary Liederman,Luisa Lopes dos Santos,Duarte Henrique Machado,Alexander Makatsariya,Alberto Maneyro,Zora Marjanovic,Serban Milhaileanu,Manuel Monreal,Sara Morais,Antonio Moreira,Mikio Mukai,Arlette Ndour,Luciana Correa Oliveira,Remedios Otero-Candelara,Maria Carolina Tostes Pintao,Florian Posch,Pascal Prilollet,Hanadi Rafii,Daniel Dias Ribeiro,Hanno Riess,Marc Righini,Helia Robert-Ebadi,Cynthia Rothschild,Andre Roussin,José Antonio Rueda Camino,Pedro Ruiz-Artacho,Gleb Saharov,Joana Santos,Maxime Sebuhyan,Ali Shamseddine,Galia Spectre Spectre,Ali Taher,Javier Trujillo-Santos,Inna Tzoran,Stéphane Villiers,Raymond Wong,Yugo Yamashita,Alexandra Yannoutsos,Chikao Yasuda
DOI: https://doi.org/10.1016/s1470-2045(22)00160-7
IF: 54.433
2022-07-01
The Lancet Oncology
Abstract:The International Initiative on Thrombosis and Cancer is an independent academic working group of experts aimed at establishing global consensus for the treatment and prophylaxis of cancer-associated thrombosis. The 2013, 2016, and 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines have been made available through a free, web-based mobile phone application. The 2022 clinical practice guidelines, which are based on a literature review up to Jan 1, 2022, include guidance for patients with cancer and with COVID-19. Key recommendations (grade 1A or 1B) include: (1) low-molecular-weight heparins (LMWHs) for the initial (first 10 days) treatment and maintenance treatment of cancer-associated thrombosis; (2) direct oral anticoagulants for the initial treatment and maintenance treatment of cancer-associated thrombosis in patients who are not at high risk of gastrointestinal or genitourinary bleeding, in the absence of strong drug-drug interactions or of gastrointestinal absorption impairment; (3) LMWHs or direct oral anticoagulants for a minimum of 6 months to treat cancer-associated thrombosis; (4) extended prophylaxis (4 weeks) with LMWHs to prevent postoperative venous thromboembolism after major abdominopelvic surgery in patients not at high risk of bleeding; and (5) primary prophylaxis of venous thromboembolism with LMWHs or direct oral anticoagulants (rivaroxaban or apixaban) in ambulatory patients with locally advanced or metastatic pancreatic cancer who are treated with anticancer therapy and have a low risk of bleeding.
oncology